D122 Renews Insurance Policies for Nearly $490,000
The New Lenox School District 122 Board of Education has renewed its property/casualty and worker’s compensation insurance policies for the 2025-2026 school year, with total costs amounting to nearly $490,000.
The board approved both renewals with the Collective Liability Insurance Cooperative (CLIC), a group of hundreds of Illinois school districts that pool resources to purchase insurance coverage at affordable rates. The upcoming school year will mark the district’s third year as a member of the cooperative.
The property and casualty insurance renewal comes at a total cost of $353,358. This policy covers the district’s buildings, property, and various forms of liability.
The worker’s compensation insurance policy was renewed for a total cost of $133,731. According to a pricing comparison sheet from CLIC, this represents a 1.6% decrease from the previous year’s cost of $135,873. The reduction is partly due to a 2.3% decrease in the modified premium, despite a 3.5% increase in the district’s total payroll.
Business Manager Robert Groos presented both renewals to the board. The measures were approved unanimously as part of the consent agenda, following a motion by board member Bill Pender and a second by Vice President David Rush.
–
Latest News Stories
Illinois Quick Hits: Fuel price drops below $4.25, still higher than in 2025
California’s billionaire tax officially heads to Nov. 3 ballot
Los Angeles County on track to raise sales tax to 10.25%
EXCLUSIVE: Individual targeted in foiled UFC terror plot speaks out
Disability-rights advocates sue Illinois over physician-assisted suicide law
Supreme Court backs gun rights for marijuana users in 9-0 decision
Iran deal omits terror proxies, ballistic missiles, human rights
‘No kings’ at $830 million Obama Center opening
Alleged UFC White House ringleader was in US illegally
‘Policy blunder’ or ‘pathway to peace’: Republicans divided over Iran deal
Second produced water treatment pilot facility online in Permian Basin
Bill provides access to customized gene therapies, medicines